Phytocannabinoids and epilepsy

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 2, 2015, Pages 135-143

  Dos Santos, R G ^a   Hallak, J E C ^a,b   Leite, J P ^a   Zuardi, A W ^a,b   Crippa, J A S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

cannabidiol; cannabinoids; delta 9 tetrahydrocannabinol; epilepsy; seizure; treatment

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABIDIVARIN; CANNABINOID; CANNABINOL; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; ENDOCANNABINOID; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; PLANT EXTRACT;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; DATA BASE; DRUG EFFECT; DRUG TOLERABILITY; EPILEPSY; HUMAN; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; ANIMAL; BIOSYNTHESIS; BRAIN CORTEX; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; METABOLISM; PHYTOTHERAPY;

ANIMALS; ANTICONVULSANTS; CANNABIDIOL; CANNABINOIDS; CEREBRAL CORTEX; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; EPILEPSY; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84924138528     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12235     Document Type: Review

References (65)

1. Mechoulam R, Carlini EA,. Toward drugs derived from cannabis. Naturwissenschaften, 1978; 65: 174-179.
2. Schultes RE, Hofmann A,. Plants of the gods: their sacred, healing, and hallucinogenic powers. Rochester: Healing Arts Press, 1992.
3. Furst PT,. Alucinõgenos y cultura. México: Fondo de Cultura Econõmica, 1994.
4. Robinson R,. The great book of hemp: the complete guide to the environmental, commercial, and medicinal uses of the world's most extraordinary plant. Rochester: Park Street Press, 1995.
5. Iversen L,. The science of marijuana. Oxford: Oxford University Press, 2000.
6. Spinella M,. The psychopharmacology of herbal medicine: plant drugs that alter mind, brain and behavior. London: The MIT Press, 2001.
7. Russo EB, Jiang HE, Li X, et al,. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot, 2008; 59: 4171-4182.
8. Crippa JA, Zuardi AW, Hallak JE,. Therapeutical use of the cannabinoids in psychiatry. Revista Brasileira de Psiquiatria, 2010; 32: S56-S66.
9. Godlaski TM,. Shiva, lord of bhang. Subst Use Misuse, 2012; 47: 1067-1072.
10. Degenhardt L, Ferrari AJ, Calabria B, et al,. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS ONE, 2013; 8: e76635.
11. Greydanus DE, Hawver EK, Greydanus MM, Merrick J,. Marijuana: current concepts. Front. Publ. Health, 2013; 1: 42.
12. Hall W, Degenhardt L,. The adverse health effects of chronic cannabis use. Drug Test Anal, 2014; 6: 39-45.
13. Ben Amar M,. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol, 2006; 105: 1-25.
14. Zuardi AW,. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria, 2008; 30: 271-280.
15. Hazekamp A, Grotenhermen F,. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids, 2010; 5: 1-21.
16. Maa E, Figi P,. The case for medical marijuana in epilepsy. Epilepsia, 2014; 55: 783-786.
17. Robson PJ,. Therapeutic potential of cannabinoid medicines. Drug Test Anal, 2014; 6: 24-30.
18. Mechoulam R, Hanus L,. Other cannabinoids. In:, Castle D, Murray RM, D'Souza DC, eds. Marijuana and madness, 2nd edn. Cambridge: Cambridge University Press, 17-22, 2012.
19. Zuurman L, Roy C, Schoemaker RC, et al,. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol, 2008; 22: 707-716.
20. Morgan CJ, Freeman TP, Schafer GL, Curran HV,. Cannabidiol attenuates the appetitive effects of delta-9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology, 2010; 35: 1879-1885.
21. Zuurman L, Roy C, Schoemaker RC, et al,. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J Psychopharmacol, 2010; 24: 363-371.
22. 9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology, 2012; 219: 885-896.
23. Gloss D, Vickrey B, Cannabinoids for epilepsy. Cochrane Database Syst Rev, 2012; 6:CD009270.
24. Gloss D, Vickrey B, Cannabinoids for epilepsy. Cochrane Database Syst Rev, 2014; 3:CD009270.
25. Zhornitsky S, Potvin S,. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals, 2012; 5: 529-552.
26. Hill AJ, Williams CM, Whalley BJ, Stephens GJ,. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther, 2012; 133: 79-97.
27. Cilio MR, Thiele EA, Devinsky O,. The case for assessing cannabidiol in epilepsy. Epilepsia, 2014; 55: 87-90.
28. Devinsky O, Cilio MR, Cross H, et al,. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014; 55: 791-802.
29. Szaflarski JP, Martina Bebin E., Cannabis, cannabidiol, and epilepsy-From receptors to clinical response. Epilepsy Behav, 2014; 41: 277-282.
30. Lutz B,. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol, 2004; 68: 1691-1698.
31. Mechoulam R,. Endocannabinoids and psychiatric disorders: the road ahead. Revista Brasileira de Psiquiatria, 2010; 32: S5-S6.
32. Brust JC, Ng SK, Hauser AW, Susser M,. Marijuana use and the risk of new onset seizures. Trans Am Clin Climatol Assoc, 1992; 103: 176-181.
33. Porter BE, Jacobson C,. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav, 2013; 29: 574-577.
34. Hamerle M, Ghaeni L, Kowski A, Weissinger F, Holtkamp M,. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol, 2014; 21: 167-170.
35. McConnell BV, Applegate M, Keniston A, Kluger B, Maa EH,. Use of complementary and alternative medicine in an urban county hospital epilepsy clinic. Epilepsy Behav, 2014; 34: 73-76.
36. Hegde M, Santos-Sanchez C, Hess CP, Kabir AA, Garcia PA,. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav, 2012; 25: 563-566.
37. Singh D, Huntwork M, Shetty V, Sequeira G, Akingbola O,. Prolonged atrial fibrillation precipitated by new-onset seizures and marijuana abuse. Pediatrics, 2014; 133: e443-e446.
38. Izquierdo I, Orsingher OA, Berardi AC,. Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia, 1973; 28: 95-102.
39. Chesher GB, Jackson DM,. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia, 1974; 37: 255-264.
40. 9-tetrahydrocannabinol on seizures in the gerbil. Eur J Pharmacol, 1975; 31: 148-152.
41. 9-tetrahydrocannabinol compared with three other drugs. Eur J Pharmacol, 1976; 35: 7-16.
42. Consroe P, Wolkin A,. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther, 1977; 201: 26-32.
43. Colasanti BK, Lindamood C 3rd, Craig CR,. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav, 1982; 16: 573-578.
44. Hofmann ME, Frazier CJ,. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol, 2013; 244: 43-50.
45. Iannotti FA, Hill CL, Leo A, et al,. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci, 2014; 5: 1131-1141.
46. V) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett, 2014; 566: 269-274.
47. Carlini EA, Leite JR, Tannhauser M, Berardi AC,. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol, 1973; 25: 664-665.
48. Turkanis SA, Cely W, Olsen DM, Karler R,. Anticonvulsant properties of cannabidiol. Res Commun Chem Pathol Pharmacol, 1974; 8: 231-246.
49. Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R,. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol, 1982; 83: 293-298.
50. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ,. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther, 2010; 332: 569-577.
51. Jones NA, Glyn SE, Akiyama S, et al,. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure, 2012; 21: 344-352.
52. Shirazi-zand Z, Ahmad-Molaei L, Motamedi F, Naderi N,. The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice. Epilepsy Behav, 2013; 28: 1-7.
53. Cunha JM, Carlini EA, Pereira AE, et al,. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980; 21: 175-185.
54. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D,. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014; 82: 1556-1563.
55. Hill AJ, Mercier MS, Hill TD, et al,. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol, 2012; 167: 1629-1642.
56. Amada N, Yamasaki Y, Williams CM, Whalley BJ,. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ, 2013; 1: e214.
57. 1 receptor-independent mechanism. Br J Pharmacol, 2013; 170: 679-692.
58. 9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia, 2010; 51: 1522-1532.
59. Wallace MJ, Martin BR, DeLorenzo RJ,. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol, 2002; 452: 295-301.
60. Monory K, Massa F, Egertová M, et al,. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron, 2006; 51: 455-466.
61. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ,. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol, 2007; 558: 52-59.
62. Falenski KW, Blair RE, Sim-Selley LJ, Martin BR, DeLorenzo RJ,. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience, 2007; 146: 1232-1244.
63. Bhaskaran MD, Smith BN,. Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS ONE, 2010; 5: e10683.
64. 1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res, 2013; 106: 74-82.
65. Vilela LR, Medeiros DC, Rezende GH, de Oliveira AC, Moraes MF, Moreira FA,. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. Epilepsy Res, 2013; 104: 195-202.